IONS - Ionis Pharmaceuticals, Inc.
61.73 0.00 (0.00%)
After hours: 4:26PM EST
| Previous Close | 61.57 |
| Open | 61.72 |
| Bid | 61.77 x 1000 |
| Ask | 62.24 x 1000 |
| Day's Range | 60.90 - 61.84 |
| 52 Week Range | 53.34 - 86.58 |
| Volume | 427,898 |
| Avg. Volume | 931,762 |
| Market Cap | 8.683B |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | 20.41 |
| EPS (TTM) | 3.03 |
| Earnings Date | Feb 25, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.06 |
- Zacks
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Moody's
UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven CMBS classes of UBSCM 2017-C3
The ratings on six P&I classes were affirmed because the transaction's key metrics, including Moody's loan-to-value (LTV) ratio, Moody's stressed debt service coverage ratio (DSCR) and the transaction's Herfindahl Index (Herf), are within acceptable ranges. The rating on the IO class was affirmed based on the credit quality of its referenced classes.
- PR Newswire
Ionis Pharmaceuticals to hold 2019 financial results webcast
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 26th at 11:30 a.m. Eastern Time to discuss its 2019 financial results and report on pipeline and business progress.
- GlobeNewswire
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman, Ph.D., to the Company’s Board of Directors, expanding the board to 11 members. Dr. Salzman has more than 30 years of experience in the pharmaceutical industry including serving as chief executive officer (CEO) of several companies, both publicly traded and private. “Amber’s experience in leading and growing successful pharmaceutical and biotechnology companies, coupled with her expertise and personal interest in rare disease, makes her a great addition to our Board,” said B. Lynne Parshall, J.D., chairman of the board at Akcea.
- Zacks
GRFS vs. IONS: Which Stock Is the Better Value Option?
GRFS vs. IONS: Which Stock Is the Better Value Option?
- PR Newswire
Ionis treatment for Alexander disease granted orphan drug status from EMA
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to ION373 for the treatment of people with Alexander disease, a severe, progressive and debilitating condition that can eventually result in death due to loss of control over autonomic functions like breathing. Infants and young children who develop the condition rarely survive beyond their teenage years or young adulthood.
- Simply Wall St.
Ionis Pharmaceuticals (NASDAQ:IONS) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Investor's Business Daily
This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run
Shares of PTC Therapeutics slipped, then rose Thursday after the biotech company unveiled disappointing Phase 3 results for its Biogen-rivaling experimental spinal muscular atrophy drug, risdiplam.
- GlobeNewswire
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Favorable safety and tolerability were observed Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid.
- Investor's Business Daily
Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?
Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study.
- PR Newswire
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-APOCIII-LRx in the treatment of patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). The study met the primary endpoint of significant triglyceride lowering and multiple secondary endpoints with a favorable safety and tolerability profile.
- MoneyShow
Top Picks 2020- Ionis Pharmaceuticals IONS
The R&D; pipeline at Ionis Pharmaceuticals (IONS) is unsurpassed, we believe, by most leading biotech and even global drug companies, suggests biotech expert Jay Silverman, contributing editor to The Medical Technology Stock Letter.
- Insider Monkey
How Did Ionis Pharmaceuticals, Inc. (IONS) Compare Against Top Hedge Fund Stocks in 2019?
We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 45.7% last year and beat the S&P 500 ETFs by […]
- GlobeNewswire
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,.
- PR Newswire
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and commercial officer reporting to Brett P. Monia, Ph.D., chief executive officer. In this newly created role, Ms. Cadoret-Manier will serve as a member of Ionis' executive leadership team and be responsible for corporate strategy, commercialization, and operational leadership.
- American City Business Journals
Johnson & Johnson spinout signs licensing, collaboration deal worth up to $1.4B
The collaboration seeks to combine technologies to develop new and more potents drugs that can be delivered to difficult to reach targets.
- PR Newswire
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
The neurological franchise of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, continued to shape the scientific and therapeutic landscape of the global biotechnology industry in 2019. By any metric, it was a remarkable year; from advancing potential breakthrough therapies in the clinic, to garnering prestigious awards and recognition in peer-reviewed journals, to generating more than $300 million in revenues. In all, Ionis' neurological franchise consists of two commercial medicines, eight drugs in late-stage development, six in early development and more than 30 in late discovery, targeting a broad range of conditions from rare diseases to those affecting millions of patients.
- PR Newswire
Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 7:30 a.m. PT in San Francisco, CA.
- GlobeNewswire
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced that results from a Phase 2 study evaluating AKCEA-APO(a)-LRx, also known as TQJ230, in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were published today in The New England Journal of Medicine (NEJM). The article is titled “Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.” For the full text of this publication, please visit: www.NEJM.org. AKCEA-APO(a)-LRx was discovered by Ionis and co-developed through Phase 2 by Akcea and Ionis.
- American City Business Journals
Experts question Cambridge biotech's strategy after trial failure
Wave Life Sciences took its first steps this week after a major corporate setback, releasing early data on one of the two potential treatments for Huntington’s disease, which it's developing with Takeda Pharmaceutical Co. Ltd. The drugs are now Wave’s most advanced products in development following its decision earlier this month to halt testing on its Duchenne muscular dystrophy treatment. In an interview with the Business Journal following the news, Wave's CEO stood by the decision to start small.
- Simply Wall St.
Why Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Looks Like A Quality Company
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Bloomberg
Here’s to Your Health: A Decade of Drug Breakthroughs
(Bloomberg Opinion) -- For all the flak the pharmaceutical industry has taken for its exorbitant pricing practices, there's no getting around the fact that it's been a pretty stunning decade for medical progress.Multiple new categories of medicines have moved from dreams and lab benches into the market and people’s lives, and investors who came along for the ride often reaped extraordinary profits. The Nasdaq Biotech Index is up 360% over the last 10 years to the S&P 500's 190%. And that’s without mentioning the hundreds of billions of dollars in takeovers that rewarded shareholders with windfalls. As 2020 approaches, it's worth highlighting how far we've come in the past 10 years in developing new therapies and approaches to treating disease, even as politicians grapple with how to rein in health-care costs without breaking an ecosystem that incentivizes the search for new discoveries. Here are some of the decade’s biggest medical breakthroughs:Cell therapies: First approved in the U.S. two years ago, these treatments still sound like science fiction. Drugmakers harvest immune cells from patients, engineer them to hunt tumors, grow them by the millions into a living drug, and reinfuse them. Yescarta from Gilead Siences Inc. and Novartis AG’s Kymriah — the two treatments approved so far — can put patients with deadly blood cancers into remission in some cases. At the beginning of the decade, academics were just beginning early patient tests. It’s still early days for the technology, and some issues are holding these drugs back. There are significant side effects, and the bespoke manufacturing process is expensive and time-consuming. That has contributed to a bruising price tag: Both of the approved medicines cost over $350,000 for a single treatment. And for now, cell therapy is mostly limited to very sick patients who have exhausted all other alternatives. Luckily, more options are on their way. Some drugmakers are focused on different types of blood cancers. Others hope to mitigate side effects or create treatments that can be grown from donor cells to reduce expenses and speed up treatment. In the longer run, companies are targeting trickier solid tumors. Scientists wouldn't be looking so far into the future without this decade’s extraordinary progress. Gene therapies: Researchers have spent years trying to figure out how to replace faulty DNA to cure genetic diseases, potentially with as little as one treatment. Scientific slip-ups and safety issues derailed a wave of initial excitement about these therapies starting in the 1990s; the first two such treatments to be approved in Europe turned out to be commercial flops. This decade, the technology has come of age. Luxturna, a treatment developed by Spark Therapeutics Inc. for a rare eye disease, became the first gene therapy to get U.S. approval in late 2017. Then in May came the approval of Novartis AG’s Zolgensma for a deadly muscle-wasting disease. The drugs have the potential to stave off blindness and death or significant disability with a single dose, and, unsurprisingly, Big Pharma has given them a substantial financial endorsement. Roche Holding AG paid $4.7 billion to acquire Spark this year, while Novartis spent $8.7 billion in 2018 to buy Zolgensma developer Avexis Inc. Dozens of additional therapies are in development for a variety of other conditions and should hit the market in the next few years. They offer the tantalizing potential not just to cure diseases, but to replace years of wildly expensive alternative treatment. If drugmakers can resist the temptation to squeeze out every ounce of value by doing things like charging $2.1 million for Zolgensma, there’s potential for these treatments to save both lives and money. RNA revolution: The above treatments modify DNA; this group uses the body’s messaging system to turn a patient’s cells into a drug factory or interrupt a harmful process. Two scientists won a Nobel Prize in 2006 for discoveries related to RNA interference (RNAi), one approach to making this type of drug, showing its potential to treat difficult diseases. That prompted an enormous amount of hype and investment, but a series of clinical failures and safety issues led large drugmakers to give up on the approach. Sticking with it into this decade paid off.Alnylam Inc. has been working since 2002 to figure out the thorny problems plaguing this class of treatments. It brought two RNAi drugs for rare diseases to the market in the past two years and has more on the way. The technology is also moving from small markets to larger ones: Novartis just paid $9.7 billion to acquire Medicines Co. for its Alnylam-developed drug that can substantially lower cholesterol with two annual treatments.Ionis Pharmaceuticals Inc. and Biogen Inc. collaborated on Spinraza, a so-called antisense drug that became the first effective treatment for a deadly rare disease. It was approved in late 2016 and had one of the most impressive drug launches of the decade. And Moderna Therapeutics rode a wave of promising messenger RNA-based medicines to the most lucrative biotechnology IPO of all time in 2018. From pharma abandonment to multiple approvals and blockbuster sales potential in under 10 years. Not bad! Cancer immunotherapy: Scientists had been working on ways to unleash the human immune system on cancers well before the 2010s without much luck. Checkpoint inhibitors — drugs that release the brakes on the body's defense mechanisms — have since produced outstanding results in a variety of cancers and are the decade’s most lucrative turnaround story. Merck got a hold of Keytruda via its 2009 acquisition of Schering-Plough, but it was far from the focus of that deal. Once Bristol-Myers Squibb & Co. produced promising results for its similar drug, Opdivo, Merck started a smart development plan that has turned Keytruda into the world’s most valuable cancer medicine. It’s now available to treat more than 10 types of the disease, and has five direct competitors in the U.S. alone. Analysts expect the category to exceed $25 billion in sales next year.If anything, the drugs may have been too successful. Copycat efforts are pulling money that could fund more innovative research. There are thousands of trials underway attempting to extend the reach of these medicines by combining them with other drugs. Some are based more on wishful thinking than firm scientific footing. Still, the ability to shrink some previously intractable tumors is a considerable advance. If drugmakers finally figure out the right combinations and competition creates pricing pressure that boosts access, these medicines will do even more in the years to come. Conquering hepatitis C: From a combined economic and public-health standpoint, a new group of highly effective hepatitis C medicines may outstrip just about anything else on this list so far. Cure rates for earlier treatments weren’t especially high; they took some time to work and had nasty side effects. The approval of Gilead’s Sovaldi in 2013, followed in time by successor drugs such as AbbVie Inc.’s Mavyret, have made hepatitis C pretty easily curable in a matter of weeks. For Gilead, getting to market rapidly with its drug proved enormously profitable; it raked in over $40 billion in revenue in just three years. Hepatitis C causes liver damage over time that can lead to transplants or cancer. The existence of a rapid cure is a significant long-term boon even if the initial pricing on the drugs made them, in some cases, prohibitively expensive. Sovaldi notoriously cost $1,000 per pill at launch and over $80,000 for a course of treatment. The good new is, treatments have become a lot more affordable, which should allow this class of drugs to have a broad and lasting positive health impact.Hepatitis C is one of the relatively few markets where the drug-pricing system has worked well. As competing medicines hit the market, the effective cost of these treatments plummeted. That, in turn, made the drugs more accessible to state Medicaid programs and prison systems, which operate on tight budgets and care for populations with higher rates of hepatitis C infection. Louisiana has pioneered the use of a “Netflix model,” under which the state paid an upfront fee for unlimited access to the drug. It’s an arrangement that will help cure thousands of patients, and other states are likely to follow its lead.Many of the medicines highlighted in this column have list prices in the six figures, a trend that’s helped drive up America’s drug spending by more than $100 billion since 2009. Building on this decade’s medical advances is going to lead to even more effective medicines that will likely come with steeper prices. I’d like to hope that policymakers will come up with a solution that better balances the need to reward innovation with the need to keep medicines accessible. That would really be a breakthrough.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
- PR Newswire
Ionis licenses investigational Alzheimer's therapy
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production of microtubule-associated protein tau (MAPT), or tau, in the central nervous system. MAPT is believed to contribute to or cause several neurodegenerative diseases, including Alzheimer's disease (AD) and some forms of frontotemporal degeneration (FTD).
